Citi initiates coverage of Gilead Sciences and Vertex Pharmaceuticals at buy in the large U.S. biotech sector. Read more here.
Investor's Business Daily on MSN3d
Vertex Pharmaceuticals Shows Rising Relative Strength; Still Shy Of Key BenchmarkA Relative Strength Rating upgrade for Vertex Pharmaceuticals shows improving technical performance. Will it continue?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback